The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022

被引：50
|
作者：
Pang, Xiaojing [1 ]
Liu, Yang [1 ]
Li, Hua [1 ,2 ]
Chen, Lixia [1 ]
机构：
[1] Shenyang Pharmaceut Univ, Wuya Coll Innovat, Key Lab Struct Based Drug Design & Discovery, Minist Educ, Shenyang 110016, Peoples R China
[2] Fujian Univ Tradit Chinese Med, Inst Struct Pharmacol & TCM Chem Biol, Coll Pharm, Fuzhou 350122, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2023年 / 257卷
基金：
中国国家自然科学基金;
关键词：
COVID-19; SARS-CoV-2; M pro inhibitors; Drug repurposing; Drug design; COVALENT INHIBITORS; GENOME SEQUENCE; ACHILLES-HEEL; CORONAVIRUS; DISCOVERY; EBSELEN; IDENTIFICATION; REPLICATION; DESIGN; 3C;
D O I：
10.1016/j.ejmech.2023.115491
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The main protease (Mpro) of SARS-CoV-2 plays a central role in viral replication and transcription and represents an attractive drug target for fighting COVID-19. Many SARS-CoV-2 Mpro inhibitors have been reported, including covalent and noncovalent inhibitors. The SARS-CoV-2 Mpro inhibitor PF-07321332 (Nirmatrelvir) designed by Pfizer has been put on the market. This paper briefly introduces the structural characteristics of SARS-CoV-2 Mpro and summarizes the research progress of SARS-CoV-2 Mpro inhibitors from the aspects of drug repurposing and drug design. These information will provide a basis for the drug development of treating the infection of SARS-CoV-2 and even other coronaviruses in the future.
引用
收藏
页数：20
相关论文
共 50 条
  • [21] Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors
    Huff, Sarah
    Kummetha, Indrasena Reddy
    Tiwari, Shashi Kant
    Huante, Matthew B.
    Clark, Alex E.
    Wang, Shaobo
    Bray, William
    Smith, Davey
    Carlin, Aaron F.
    Endsley, Mark
    Rana, Tariq M.
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (04) : 2866 - 2879
  • [22] Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease
    Katagishi, Daiki
    Yasuda, Daisuke
    Takahashi, Kyoko
    Nakamura, Shigeo
    Mashino, Tadahiko
    Ohe, Tomoyuki
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 80
  • [23] Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors
    Khatua, Kaustav
    Alugubelli, Yugendar R.
    Yang, Kai S.
    Vulupala, Veerabhadra R.
    Blankenship, Lauren R.
    Coleman, Demonta
    Atla, Sandeep
    Chaki, Sankar P.
    Geng, Zhi Zachary
    Xiao, Jing
    Chen, Peng-Hsun
    Cho, Chia-Chuan D.
    Sharma, Shivangi
    Vatansever, Erol C.
    Ma, Yuying
    Yu, Ge
    Neuman, Benjamin W.
    Xu, Shiqing
    Liu, Wenshe Ray
    ANTIVIRAL RESEARCH, 2024, 225
  • [24] Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors
    Ullrich, Sven
    Sasi, Vishnu M.
    Mahawaththa, Mithun C.
    Ekanayake, Kasuni B.
    Morewood, Richard
    George, Josemon
    Shuttleworth, Laura
    Zhang, Xiaobai
    Whitefield, Cassidy
    Otting, Gottfried
    Jackson, Colin
    Nitsche, Christoph
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 50
  • [25] Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro)
    Katre, Soumya Gulab
    Asnani, Alpana Jagdish
    Pratyush, Kumar
    Sakharkar, Nilima Gangadhar
    Bhope, Ashwini Gajanan
    Sawarkar, Kanchan Tekram
    Nimbekar, Vaibhav Santosh
    FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 8 (01)
  • [26] Molecular Docking Unveils Prospective Inhibitors for the SARS-COV-2 Main Protease
    Ahmad, Fawad
    Ikram, Saima
    Ahmad, Jamshaid
    Rehman, Irshad Ur
    Khattak, Saeed Ullah
    Butt, Sadia
    Mushtaq, Maryam
    SAINS MALAYSIANA, 2021, 50 (05): : 1473 - 1484
  • [27] Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors
    Bhardwaj, Vijay Kumar
    Singh, Rahul
    Sharma, Jatin
    Rajendran, Vidya
    Purohit, Rituraj
    Kumar, Sanjay
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2021, 39 (10) : 3449 - 3458
  • [28] Inhibitors of SARS-CoV-2 main protease: Biological efficacy and toxicity aspects
    Viskupicova, Jana
    Rezbarikova, Petronela
    Kovacikova, Lucia
    Kandarova, Helena
    Majekova, Magdalena
    TOXICOLOGY IN VITRO, 2023, 92
  • [29] Drug repurposing and computational modeling for discovery of inhibitors of the main protease (Mpro) of SARS-CoV-2
    Silva, Jose Rogerio A.
    Kruger, Hendrik G.
    Molfetta, Fabio A.
    RSC ADVANCES, 2021, 11 (38) : 23450 - 23458
  • [30] Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors
    Fiorucci, Diego
    Milletti, Eva
    Orofino, Francesco
    Brizzi, Antonella
    Mugnaini, Claudia
    Corelli, Federico
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2021, 39 (16) : 6242 - 6248
12345